Related Experiment Video
Updated: Mar 9, 2026
17:42
A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation
Published on: April 13, 2011
66.1K
Does exercise pose a challenge to glucoregulation after clinical islet transplantation?
Deanna R Funk1, Normand G Boulé2, Peter A Senior3
1a Augustana Faculty, University of Alberta., 4901 - 46th Avenue Camrose, AB T4V 2R3, Canada.
Summary
Islet transplantation (ITx) improves glucose control in type 1 diabetes but doesn't fully restore it. Physical activity may impact graft survival, though research in human recipients is lacking.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Transplantation Immunology
Background:
- Islet transplantation (ITx) restores insulin secretion in type 1 diabetes (T1D), yet glucose regulation remains imperfect.
- Physical activity is known to influence beta-cell function and mass in diabetes models.
- The potential role of physical activity in ITx graft survival warrants investigation.
Purpose of the Study:
- To review current knowledge on physical activity in ITx recipients.
- To examine human ITx recipient responses to hypoglycemia.
- To assess the impact of physical activity on ITx outcomes.
Main Methods:
- Systematic literature search of PubMed, Medline, and Embase.
- Inclusion criteria focused on ITx recipients, physical activity, hypoglycemia, and hormonal responses.
- Analysis of 277 English language publications.
Main Results:
- Human ITx recipients show normal insulin suppression during induced hypoglycemia.
- Animal studies on exercise in ITx recipients yield conflicting results, influenced by time and site.
- No studies directly assessed blood glucose responses to physical activity in human ITx recipients.
Conclusions:
- ITx significantly improves but does not fully normalize glucose homeostasis.
- Counterregulatory responses to glycemic challenges remain suboptimal post-ITx.
- Further research is needed on physical activity's role in human ITx recipients.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.9K
01:16Hormones Regulating Blood Glucose
7.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.9K
01:16Insulin: Dosing Regimen and Adverse Effects
1.0K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:02Glucose Homeostasis: Regulation of Blood Glucose
4.9K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.9K